atezolizumab,bevacizumab,cetuximab,obinutuzumab,panitumumab
roche,eli lilly,biogen,amgen,takeda
['crc,(-ccrcc),(-tbcrc049),(-mccrcc),(-mbcrc)', 'fire-4', 'crcsm', 'fluoro']
1) #ras mt after 1st anti-egfr in remarry -&gt; phii pursuit neg w/orr 14% w/irino-pmab rechallenge, 2) switch maint to fluoro-bev not superior to folfiri-cmab until pd in phiii fire-4, 3) phii adding meki w/pmab in egfri-refractory did not overcome acq resist adv #crcsm #asco22 
Medical oncologist and researcher in gastrointestinal and genitourinary cancers @CedarsSinai. Hematology/Oncology fellowship @cityofhope